You are here:Home>World Parkinson’s Awareness Day 2019
April 11, 2019 is World Parkinson’s Awareness Day and we are commemorating this day by offering a 20% discount voucher off all Parkinson’s reports. Apply parkinsons20 at checkout to gain a 20% discount.
Access reports that include a disease overview, market forecast, treatment, and future trends for this chronic and progressive neurodegenerative disorder, characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability.
Parkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. The condition is caused by the degeneration of dopamine-producing cells of the substantia nigra. Parkinson’s disease is incurable, but non-fatal, resulting in poor quality of life and increasing disability as the disease progresses.
Datamonitor Healthcare interviewed two neurologists, one based in Italy and the other in the US, to gauge their prescribing habits and views on current treatment options and challenges, late-stage clinical candidates and pricing and reimbursement considerations for Parkinson’s disease. The drugs discussed are listed below. The two interviews were combined into a single report.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.